2014-12-19 14:00:53 UTC

Steroid-Based Treatment May Answer Needs of Pediatric EoE Patients

Bethesda, MD (Dec. 19, 2014) — A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study1 in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. Eosinophilic esophagitis is a chronic immune system disease caused by a buildup of white blood cells in the lining of the esophagus. This build up, which is a reaction to food, allergens or acid reflux, can inflame or injure esophageal tissue resulting in problems such as difficulty swallowing, vomiting and need for emergency procedures due to food getting stuck in the esophagus.

“EoE patients struggle daily, as the damage to their esophagus makes swallowing and eating a formidable challenge,” said Sandeep K. Gupta, MD, lead study author from Indiana University School of Medicine and Riley Hospital for Children, Indianapolis. “There is a dire need for a safe and effective EoE treatment, as currently, there are no FDA-approved treatments for this condition. Oral budesonide suspension demonstrated remarkable efficacy to reduce eosinophilic inflammation in our study, offering hope for EoE patients.”

Researchers conducted a prospective, randomized, double-blind, placebo-controlled study to assess the effectiveness and safety of oral budesonide suspension — a new, proprietary, oral formulation of budesonide — in children and adolescents (ages 2-18) with EoE. Patients were randomly assigned to groups given placebo, low-dose, medium-dose or high-dose therapy for 12 weeks. At the end of 12 weeks, histologic (improved tissue) response was achieved in more than 50 percent of patients in the medium-dose group and in more than 90 percent of patients in the high-dose group. Only 5.6 percent of patients in the placebo group experienced improved histologic response; there was no significant difference in percentages of responders between the low-dose and placebo groups. Oral budesonide suspension was safe at all doses and there were no serious drug-related adverse events.

While EoE patients experienced significant histologic response in the medium- and high-dose groups, patients in all four groups experienced comparable symptom responses. Further research is needed to assess this treatment’s ability to improve symptoms.

Oral budesonide suspension is designed to coat the esophagus with budesonide in order to treat local eosinophilic inflammation. Budesonide — a glucocorticoid steroid — is the active pharmaceutical ingredient in several products approved by the U.S. FDA, including products for the treatment of pediatric and adult asthma, allergic rhinitis, chronic obstructive pulmonary disease and Crohn's disease.

This study was sponsored by Meritage Pharma, Inc.

1 Gupta, Sandeep K., et al. Efficacy and Safety of Oral Budesonide Suspension in Pediatric Patients With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology 2015: 13(1): 66-76.e5
 

About the AGA Institute 

The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to include more than 16,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization. www.gastro.org.
 

About Clinical Gastroenterology and Hepatology

The mission of Clinical Gastroenterology and Hepatology is to provide readers with a broad spectrum of themes in clinical gastroenterology and hepatology. This monthly peer-reviewed journal includes original articles as well as scholarly reviews, with the goal that all articles published will be immediately relevant to the practice of gastroenterology and hepatology. For more information, visit www.cghjournal.org.
 
Follow us on Twitter @AmerGastroAssn
Check out our videos on YouTube.